IPO Listed — 19 May 2026
Listing Price: ₹59.75
Goldline Pharmaceutical SME IPO GMP History | Listing Price ₹59.75 & Kostak Rate
Goldline Pharmaceutical SME IPO has been listed on May 19, 2026 at a listing price of ₹59.75, against the issue price of ₹43 — a gain of ₹16.75 (+38.95%). The GMP peaked at ₹25 on 13 May 2026 and reached a low of ₹8 on 9 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Goldline Pharmaceutical SME IPO raised ₹12 Cr. through its IPO at a price band of ₹41 to ₹43 per share, with a lot size of 3000 shares. The IPO was open for subscription from 12 May 2026 to 14 May 2026.
Table of Contents
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 18 May 2026 | ₹ 15 | 35% | ₹ 0 | ₹ 0 | |
| 17 May 2026 | ₹ 20 | 47% | ₹ 0 | ₹ 0 | |
| 15 May 2026 | ₹ 18 | 42% | ₹ 0 | ₹ 0 | |
| 14 May 2026 | ₹ 15 | 35% | ₹ 0 | ₹ 0 | |
| 13 May 2026 | ₹ 25 | 58% | ₹ 0 | ₹ 0 | |
| 12 May 2026 | ₹ 18 | 42% | ₹ 0 | ₹ 0 | |
| 11 May 2026 | ₹ 17 | 40% | ₹ 0 | ₹ 0 | |
| 10 May 2026 | ₹ 15 | 35% | ₹ 0 | ₹ 0 | |
| 09 May 2026 | ₹ 8 | 19% | ₹ 0 | ₹ 0 | |
| 08 May 2026 | ₹ 8 | 19% | ₹ 0 | ₹ 0 |
Goldline Pharmaceutical SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 12 May, 2026 |
| Close Date | 14 May, 2026 |
| Allotment Date | 15 May, 2026 |
| Refund Date | 18 May, 2026 |
| Credit to Demat | 18 May, 2026 |
| Listing Date | 19 May, 2026 |
Goldline Pharmaceutical SME IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹43 |
| GMP-Based Estimate (Pre-Listing) | ₹58 (+34.9%) |
| Actual Listing Price | ₹59.75 (+38.95%) |
| Listing Gain / Loss | +₹16.75 per share |
| Listing Date | 19 May, 2026 |
Is Goldline Pharmaceutical SME IPO GMP Reliable?
Grey market premium for Goldline Pharmaceutical SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Goldline Pharmaceutical SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Goldline Pharmaceutical SME IPO IPO Kostak Rate Explained
The Kostak rate for Goldline Pharmaceutical SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Goldline Pharmaceutical SME IPO
The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.
Strengths & Risks
Strengths
- ✓ Asset-light business model reduces manufacturing costs and improves operational scalability significantly.
- ✓ Diversified pharmaceutical portfolio caters to multiple therapeutic and healthcare treatment segments.
- ✓ Strong doctor and distributor network supports consistent product demand across regions.
- ✓ Experienced promoters with pharmaceutical industry knowledge help drive business expansion plans.
Risks
- ⚠ Dependence on third-party manufacturers may impact product quality and timely supply.
- ⚠ Highly competitive pharmaceutical industry can pressure margins and market share growth.
- ⚠ Revenue concentration in domestic markets increases dependence on Indian pharmaceutical demand.
- ⚠ Regulatory changes in healthcare sector may affect operations and product approvals.
- ⚠ Smaller business scale compared to major pharma companies limits competitive advantages currently.
Frequently Asked Questions about Goldline Pharmaceutical SME IPO
What is the GMP of Goldline Pharmaceutical SME IPO?
The current Grey Market Premium (GMP) of Goldline Pharmaceutical SME IPO is ₹ 15.
What is the Kostak Price of Goldline Pharmaceutical SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Goldline Pharmaceutical SME IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What is the Subject to Sauda Price of Goldline Pharmaceutical SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What was the actual listing price of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO listed on May 19, 2026 at ₹59.75, against the issue price of ₹43 — a gain of +38.95%.
How did the GMP of Goldline Pharmaceutical SME IPO trend before listing?
The GMP of Goldline Pharmaceutical SME IPO was falling in its final days before listing. The GMP peaked at ₹25 on 13 May 2026. View the day-wise table above for the complete GMP history.
Explore Goldline Pharmaceutical SME IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!